Skip to main content
. Author manuscript; available in PMC: 2013 Oct 28.
Published in final edited form as: Cancer Gene Ther. 2012 Nov 9;20(1):17–24. doi: 10.1038/cgt.2012.75

Figure 4.

Figure 4

Increased antiangiogenic effects ofNV1042/vinblastine combination in an in vitro tube formation assay. HUVEC cells were plated on matrigel-coated plates and either remained untreated (Neg.) or treated with NV1023 or NV1042 (MOI 1), vinblastine (1nM) or their combination. Twentyhrs later, tube formation was scored. Representative fields are shown for each condition (A) and the number of tubes/field was quantified (B). Each treatment was performed in triplicate. Student’s t test was used to determine statistical significance between the indicated control and treatment groups. Bars represent average ± S.E.M..*, P< 0.01 for NV1023+VB and NV1042+VB verses NV1023 alone, NV1042 alone, VB alone or untreated.